NZ575918A - Treatment and/or prevention of non-infectious medical conditions using antibody-containing milk or egg products - Google Patents

Treatment and/or prevention of non-infectious medical conditions using antibody-containing milk or egg products

Info

Publication number
NZ575918A
NZ575918A NZ575918A NZ57591807A NZ575918A NZ 575918 A NZ575918 A NZ 575918A NZ 575918 A NZ575918 A NZ 575918A NZ 57591807 A NZ57591807 A NZ 57591807A NZ 575918 A NZ575918 A NZ 575918A
Authority
NZ
New Zealand
Prior art keywords
antibody
ephb4
cancer
containing milk
egg product
Prior art date
Application number
NZ575918A
Other languages
English (en)
Inventor
Antony William Scammell
Original Assignee
A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904752A external-priority patent/AU2006904752A0/en
Application filed by A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust filed Critical A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust
Publication of NZ575918A publication Critical patent/NZ575918A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ575918A 2006-08-31 2007-08-31 Treatment and/or prevention of non-infectious medical conditions using antibody-containing milk or egg products NZ575918A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2006904752A AU2006904752A0 (en) 2006-08-31 Uses for Antibodies
PCT/AU2007/001282 WO2008025099A1 (en) 2006-08-31 2007-08-31 Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions

Publications (1)

Publication Number Publication Date
NZ575918A true NZ575918A (en) 2012-03-30

Family

ID=39135433

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ575918A NZ575918A (en) 2006-08-31 2007-08-31 Treatment and/or prevention of non-infectious medical conditions using antibody-containing milk or egg products

Country Status (8)

Country Link
US (2) US20100297140A1 (https=)
EP (1) EP2061510B1 (https=)
JP (1) JP2010501596A (https=)
CN (1) CN101626784B (https=)
AU (1) AU2007291891B2 (https=)
DK (1) DK2061510T3 (https=)
NZ (1) NZ575918A (https=)
WO (1) WO2008025099A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
CA2760096C (en) 2009-04-27 2018-10-30 Immuron Limited Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder.
JP2011026252A (ja) * 2009-07-27 2011-02-10 Kitasato Institute 上皮成長因子受容体に対する卵黄抗体およびその用途
WO2012023051A2 (en) 2010-08-17 2012-02-23 Immuron Ltd. Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
MY164281A (en) 2010-11-23 2017-11-30 Pantheryx Inc Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
NZ611428A (en) * 2010-12-08 2015-07-31 Stemcentrx Inc Novel modulators and methods of use
WO2012098256A1 (en) * 2011-01-21 2012-07-26 Université De La Méditerranée Aix - Marseille Ii Anti-cd146 auto-antibodies and uses thereof
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
EP2786156A2 (en) * 2011-11-30 2014-10-08 AbbVie Deutschland GmbH & Co KG Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
JP2016540826A (ja) 2013-11-04 2016-12-28 ファイザー・インク 抗ｅｆｎａ４抗体−薬物コンジュゲート
RO130965A8 (ro) * 2015-10-16 2017-06-30 Romvac Company S.A. Producerea şi utilizarea oului hiperimun personalizat () în tratamentul psoriazisului
US10792320B2 (en) * 2018-03-28 2020-10-06 Michael Alan Beller Methods for treatment of bladder dysfunction
WO2020176637A1 (en) 2019-02-26 2020-09-03 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
US11319382B1 (en) 2021-06-28 2022-05-03 King Abdulaziz University Methods for producing and using IgY antibodies targeting the middle east respiratory syndrome coronavirus spike protein to treat or prevent MERS-CoV infection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3911108A (en) * 1973-02-14 1975-10-07 Diamond Shamrock Corp Process of producing bovine milk products containing specific antibodies
AUPN642795A0 (en) * 1995-11-08 1995-11-30 Northfield Laboratories Pty Ltd Dairy compositions and methods of preparing same
NZ335170A (en) * 1996-10-02 2001-08-31 Ovimmune Inc Oral administration of chicken yolk Ig-gamma antibodies to treat disease
AU2115799A (en) * 1998-01-19 1999-08-02 Dcv, Inc. Composition and method for treatment and prevention of arthritis and/or autoimmune diseases
WO1999064069A1 (en) * 1998-06-10 1999-12-16 Ophidian Pharmaceuticals, Inc. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
CN1163511C (zh) * 1999-10-22 2004-08-25 徐永华 鸡卵黄抗白细胞介素-8抗体、制备方法及其应用
CN1303889A (zh) 1999-12-20 2001-07-18 陶氏康宁东丽硅氧烷株式会社 用于嵌件模塑或双模腔模塑的硅橡胶组合物
JP2005298332A (ja) * 2000-09-28 2005-10-27 Shibayagi:Kk 過剰自己抗体産生抑制物質、その製造法およびその使用方法
US20050175597A1 (en) * 2002-03-21 2005-08-11 Rawlin Grant T. Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment
CN1199672C (zh) 2002-04-17 2005-05-04 李永忠 一套预防与治疗癌症中成药
CN1377894A (zh) * 2002-04-23 2002-11-06 郭占军 蛋黄抗癌抗体制备方法及其应用
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
JP4264894B2 (ja) * 2004-03-01 2009-05-20 三菱自動車工業株式会社 エアボックス付きグローブボックス
CN101072797B (zh) * 2004-03-12 2012-05-09 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
AU2005299767A1 (en) * 2004-10-21 2006-05-04 The Penn State Research Foundation Eph receptor tumor biomarkers
JP2008537673A (ja) * 2005-01-31 2008-09-25 ジェネンテック・インコーポレーテッド 抗ｅｐｈｂ２抗体とその使用方法
AU2006285850A1 (en) 2005-08-29 2007-03-08 Japan Science And Technology Agency Antibody produced using ostrich and method for production thereof

Also Published As

Publication number Publication date
AU2007291891B2 (en) 2013-10-31
EP2061510B1 (en) 2016-06-22
JP2010501596A (ja) 2010-01-21
CN101626784B (zh) 2013-07-17
US20100297140A1 (en) 2010-11-25
DK2061510T3 (en) 2016-09-05
CN101626784A (zh) 2010-01-13
EP2061510A1 (en) 2009-05-27
US20130295109A1 (en) 2013-11-07
WO2008025099A1 (en) 2008-03-06
US8834872B2 (en) 2014-09-16
AU2007291891A1 (en) 2008-03-06
EP2061510A4 (en) 2011-01-05

Similar Documents

Publication Publication Date Title
US8834872B2 (en) Uses of antibodies
JP7342701B2 (ja) 癌の治療及び／又は予防用医薬組成物
JP6359492B2 (ja) 抗ＩＬ−１α抗体による癌の処置方法
TWI852695B (zh) 抗體-藥物結合物之用途
JP4854912B2 (ja) 癌に対する抗体
TW201815423A (zh) 免疫性／治療性聚醣組合物及其用途
US20120266264A1 (en) Monoclonal antibodies against gonadotropin-releasing hormone receptor
BR112019008335A2 (pt) conjugado de um anticorpo, composição farmacêutica e método para o tratamento e/ou a prevenção de um câncer
JP2017518958A (ja) 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
JP7470154B2 (ja) 尿路上皮がんの治療における抗ｈｅｒ２抗体－薬物コンジュゲートの使用
JP2005508839A (ja) ペプチドおよびｍｕｃ１タンパク質に対する抗体
JP2023553773A (ja) 抗ｈｍｍｗ抗体、それを含む組成物、及びそれをコードする核酸分子、並びにその使用
JP2022046576A (ja) 炎症性障害の治療療法
CN116059392B (zh) 配体偶联物及其应用
TWI862564B (zh) 癌治療用醫藥
CN114225025A (zh) 含有益生菌的制剂在治疗肠胃疾病中的应用
CN114225024B (zh) 一种用于治疗疾病的益生菌药物
WO2019045025A1 (ja) ワクチン組成物
CN120795151A (zh) 抗犬pd-l1单克隆抗体及其在制备抗癌药物方面的应用
JPH09278668A (ja) Ｈｓｐ２７ファミリーに属するタンパク質の麦芽抽出物含有合成抑制剤
CN121002061A (zh) 抗cith3抗体及其用途
JP2011026252A (ja) 上皮成長因子受容体に対する卵黄抗体およびその用途
WO2020256110A1 (ja) タイトジャンクション形成誘導剤

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 31 AUG 2017 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20140502

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 31 AUG 2027 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20140716

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 31 AUG 2020 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20140716